Cerebral toxoplasmosis in patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab

被引：3
|
作者：
Raquel, Calle-Calle [1 ]
Lucia, Triguero-Cueva [1 ]
Carmen, Valderrama-Martin [1 ]
Ana, Romero-Villarrubia [1 ]
Antonio, Tapia-Gomez [2 ]
Juan, Pasquau-Liano [2 ]
Carmen, Arnal-Garcia [1 ]
机构：
[1] Univ Hosp Granada, Dept Neurol Virgen Nieves, Granada, Spain
[2] Univ Hosp Granada, Unit Infect Dis Virgen Nieves, Granada, Spain
来源：
MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2020年 / 39卷
关键词：
Alemtuzumab; Multiple sclerosis; Toxoplasmosis;
D O I：
10.1016/j.msard.2019.101885
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797
  • [2] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [3] Primary cytomegalovirus infection in a patient with relapsing-remitting multiple sclerosis under treatment with alemtuzumab
    Eichau, S.
    Lopez Ruiz, R.
    Caston Osorio, J. J.
    Ramirez, E.
    Dominguez-Mayoral, A.
    Izquierdo, G.
    NEUROLOGIA, 2020, 35 (06): : 440 - 443
  • [4] Alopecia totalis following alemtuzumab treatment in relapsing-remitting multiple sclerosis
    Zimmermann, J.
    Buhl, T.
    Mueller, M.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 382 - 382
  • [5] Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
    Alcala, C.
    Gascon, F.
    Perez-Miralles, F.
    Dominguez, J. A.
    Garcia Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 274 - 274
  • [6] Safety of alemtuzumab by treatment course in patients with active relapsing-remitting multiple sclerosis
    Clanet, M.
    Hunter, S. F.
    Palmer, J.
    Oyuela, P.
    Margolin, D. H.
    JOURNAL OF NEUROLOGY, 2014, 261 : S300 - S300
  • [7] Safety of alemtuzumab by treatment course in patients with active relapsing-remitting multiple sclerosis
    Clanet, M.
    Hunter, S. F.
    Palmer, J.
    Oyuela, P.
    Margolin, D. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 453 - 453
  • [8] Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis
    Brown, J. William L.
    Coles, Alasdair J.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2013, 7 : 131 - 138
  • [9] Immunogenicity of alemtuzumab treatment for relapsing-remitting multiple sclerosis: no effect on efficacy or safety
    Selmaj, K.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247
  • [10] Alemtuzumab induces severe orbitopathy in relapsing-remitting multiple sclerosis
    Gomez, Pablo Rodriguez de Vera
    Muros, Mariola Mendez
    Cuadro, Alberto Torres
    de Miera, Francisco Javier Toyos Saenz
    Ruiz, Rocio Lopez
    Vazquez, Raquel Guerrero
    Gonzalez, Juan Jesus Garcia
    Hermosilla, Antonio Manuel Garrido
    Hernandez, Tomas Martin
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 486 - 496
12345